Prioritizing Human Use Antibiotics for Environmental Health Management and Estimating Their Environmental Concentrations in Korean Waterway

인체용 항생제의 우선관리대상 선정과 물환경 중 오염농도 추정

  • Published : 2006.10.31

Abstract

Antibiotics are manufactured and used for specific physiological functions, hence they may exert adverse ecological consequences when they are in contact with nontarget organisms. In the last decade, many reports have been made on the occurrences of various antibiotic compounds in surface water, and their potential impact to the environment has become an increasing concern. This study was conducted to prioritize antibiotic substances with potential environment risk in Korea. Human use antibiotics with an EIC (Expected Introduction Concentration) value greater than $1{\mu}g/l$, US FDA's action limit criteria, were selected. In order to calculate a worst-case EIC for each substance, annual production volume (in kg) of each antibiotic substance was derived using the Korea Pharmaceutical Manufacturers Association (KPMA)'s monetary database. Sixteen substances were preliminarily selected. The EICs of the 16 antibiotic substances were refined with the excretion rate of the parent substances. Ten antibiotic substances were identified to have EIC-corrected greater than $1{\mu}g/l$, which include Amoxicillin ($15.8{\mu}g/l$), Cefaclor ($10.1{\mu}/l$), Roxithromycin ($4.2{\mu}g/l$), Cephradine ($4.5{\mu}g/l$), Cefatrizine ($2.6{\mu}g/l$), Cefadroxil ($3.3{\mu}g/l$), Aztreonam ($2.3{\mu}g/l$), Ceftazidime ($2.8{\mu}g/l$), Ribostamycin ($1.3{\mu}g/l$), and Ceftezole ($1.3{\mu}g/l$). Additional risk assessments for these antibiotic substances are suggested.

Keywords

References

  1. 환경부 : 위해우려물질 선정 및 평가 연구, 2003
  2. Park, J. : P harmaceuticals in the Environment and Management Approaches in Korea. Korea Environment Institute, 2005
  3. Roberts, P. H. and Thomas, K. V. : The occurrence of selected pharmaceuticals in wastewater effluent and surface waters of the lower Tyne catchment. Science of the Total Environment, 356, 143-153, 2006 https://doi.org/10.1016/j.scitotenv.2005.04.031
  4. Jjemba, P. K. : Excretion and ecotoxicology of pharmaceutical and personal care products in the environment. Ecotoxicology and Environmental Safety, 63, 113-120, 2006 https://doi.org/10.1016/j.ecoenv.2004.11.011
  5. Tarazona, J. V., Buzby, M. E., Hartmann, A., Housenger, J. E., Olejniczak, K., Sager, N. B., Servos, M. R. and Tolson, N . D. : Scientific basis for aquatic environmental risk assessment of human pharmaceuticals in human pharmaceuticals - assessing the impacts on aquatic ecosystems edited by Richard T. Williams, SETAC press, 269-302, 2005
  6. Sanderson, H., Johnson, D. J., Reitsma, T., Brain, R. A., Wilson, C. J. and Solomon, K. R. : Ranking and prioritization of environmental risks of pharmaceuticals in surface waters. Regulatory Toxicology and Pharmacology, 39, 158-183, 2004 https://doi.org/10.1016/j.yrtph.2003.12.006
  7. Kummerer, K. : Pharmaceuticals in the Environment - Source, Fate, Effects and Risks. Springer Berlin Heidelberg, 2004
  8. Jones, O. A. H., Voulvoulis, N. and Lester, J. N. : Aquatic environmental assessment of the top 25 English prescription pharmaceuticals. Water Research, 36, 5013-5022, 2002 https://doi.org/10.1016/S0043-1354(02)00227-0
  9. Han, G. H., Hur, H. G. and Kim, S. D. : Ecotoxicological risk of pharmaceuticals from wastewater treatment plants in Korea; Occurrence and toxicity to Daphnia magna. Environmental Toxicology and Chemistry, 25(1), 265-271, 2006 https://doi.org/10.1897/05-193R.1
  10. Kang, H. J., Kim, H. S., Choi, K. H., Kim, K. T. and Kim, P. G. : Several human pharmaceutical residues in aquatic environment may result in endocrine Disruption in Japanese Medaka (Oryzias latipes). Korean Journal of Environmental Health, 31(3), 227-233, 2005
  11. Kang, H. J., Choi, K. H., Kim, M. Y. and Kim, P. G. : Endocrine disruption induced by some sulfa drugs and tetracyclines on oryzias latipes. Korean Journal of Environmental Health, 32(3), 227-234, 2006
  12. US FDA : Guidance for the Industry : Environmental Assessment of Human Drug and Biologics Applications, 1998
  13. EMEA : Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use, 2005
  14. 한국제약협회 : 2003년 약효별 실적분류 데이터베이스, 2003
  15. 이의경, 장선미, 박은자, 석옥경, 김의종, 허정식 : 항생제 내성발생요인에 관한 상관성 연구. 한국보건사회연구원, 식품의약품안전청, 2002
  16. 장민기, 추정민, 이혜수, 김정수 : 전북대학교병원에서 분리된 그람음성균의 항생제 내성률의 변동과 약물 사용과의 관계. 소아과, 43(5), 625-637, 2000
  17. 식품의약품안전청 : 의약품등분류번호에관한규정, 1998
  18. 대한민국의약성분센터 KIMS OnLine, http://kimsonline.co.kr/
  19. 환경부, 한국토지공사 : 주택단지내 상수.오수 발생량 원단위 산정 및 하수처리시설 소용 비용 연구. 2001
  20. 통계청, http://www.nso.go.kr
  21. Hirsch, R., Ternes, T., Haberer, K. and Kratz, K. L. : Occurrence of antibiotics in the aquatic environment. The Science of the Total Environment, 225, 109-118, 1999 https://doi.org/10.1016/S0048-9697(98)00337-4
  22. Mastrandrea, V., Ripa, S., La Rosa, F. and Ghezzi, A. : Pharmacokinetics of cefatrizine after oral administration in human volunteers. International Journal of Clinical Pharmacology Research, 5(5), 319-23, 1985
  23. Information for Health Professionals, http://www.medsafe.govt.nz
  24. Rx List(The Internet Drug Index), http://www.rxlist.com
  25. Cutler, R. E ., Blair, A . D. and Kelly, M . R. : Cefadroxil kinetics in patients with renal insufficiency. Infection, 8(5), S592-S597, 1980 https://doi.org/10.1007/BF01639677
  26. Rittenbury, M. S. : How and why aztreonam works. Surgery, Gynecology & Obstetrics, 171, 19-23, 1990
  27. IPCS Inchem., http://www.inchem.org
  28. 신풍제약 주식회사, http://www.shinpoong.co.kr
  29. Nishida, M., Murakawa, T., Kamimura, T., Okada, N., Sakamoto, H., Fukada, S,, Nakamoto, S., Yokota, Y. and Miki, K. : In Vitro and In Vivo Evaluation of Ceftezole, a New Cephalosporin Derivative. Antimicrobial Agents and Chemotherapy, 10(1), 1-13, 1976 https://doi.org/10.1128/AAC.10.1.1
  30. Elephant Care International, http://www.elephantcare.org
  31. Gold Standard Inc., http://gsm.about.com